drugset / Trial / NCT00085488

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00085488

Treatment

Summary

RATIONALE: Vaccines made from a patient's dendritic cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

Timeline

Start
2004-02
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous tumor cell vaccine Vaccine Intravenous
Subject therapeutic autologous dendritic cells Vaccine Intravenous

Indications